Revolution Medicines COO Sells Thousands of Shares Under 10b5-1 Plan, Retains 150,000 Shares

Margaret A. Horn, Chief Operating Officer of U.S. oncology biotech company Revolution Medicines, Inc. (RVMD), exercised stock options on June 15 and 17 to acquire common shares and then, under a pre-established Rule 10b5-1 trading plan, sold tens of thousands of those shares at roughly $160 each. Even after these two rounds of option exercises and subsequent sales, COO Horn still directly holds approximately 150,000 common shares, and the company’s filing notes that a significant number of restricted stock units remain scheduled to vest.

The company recently reported positive results—including improved overall survival—in the global Phase 3 RASolute-302 trial of its oral pancreatic cancer candidate Daraxonlasib. In May, it received early access authorization from the U.S. Food and Drug Administration for patients with treatment-naive advanced pancreatic cancer, and in April it raised about $2.1 billion (approximately KRW 3 trillion) through a combined offering of common stock and convertible notes.

Headquartered in Redwood City, California, Revolution Medicines is an oncology drug developer with a small-molecule pipeline targeting RAS-addicted solid tumors driven by RAS mutations. Its lead candidate, Daraxonlasib, is undergoing global development for hard-to-treat solid tumors, including pancreatic cancer, and in 2025 it earned Breakthrough Therapy designation from the FDA for the pancreatic cancer indication.